Biomarker proxies on ODP Holes 151-912A and 151-912B

A novel and promising biomarker proxy for reconstruction of Arctic sea ice conditions was developed and is based on the determination of a highly branched isoprenoid with 25 carbons (IP25). IP25 records have been restricted to the last 150 kyr BP. We present a biomarker record from Ocean Drilling Program (ODP) Site 912, going back to the Pliocene-Pleistocene boundary and indicating that sea ice of variable extent occurred in the Fram Strait/southern Yermak Plateau area at least since about 2.2 Ma. Furthermore, our data support the idea that a combination of IP25 and open water, phytoplankton biomarker data ("PIP25 index") may give a more reliable and quantitative estimate of past sea ice cover (at least for the study area). The study reveals that the novel IP25/PIP25 biomarker approach has potential for semi-quantitative paleo-sea ice studies covering the entire Quaternary and could motivate further detailed high resolution research on ODP/IODP material using this proxy.

Análise Retrospectiva e Caracterização Epidemiológica de 151 Casos de Inflamação Ocular

Objectivo: Analisar e caracterizar uma amostra de doentes de uma consulta de inflamação ocular. Material e Métodos: Análise retrospectiva de 503 consultas realizadas por um clínico entre 1 de Agosto de 2012 e 31 de Agosto de 2013 no Centro Hospitalar de Lisboa Central com recurso aos respectivos processos clínicos. Na análise da casuística da consulta foram incluídos 151 doentes. Desses, 24 padeciam de doenças auto-imunes em seguimento para monitorização de toxicidade a fármacos mas sem registo de qualquer episódio de uveíte, pelo que foram excluídos da avaliação estatística referente às uveítes. Dos 127 doentes com uveíte foram incluídos 197 olhos. Resultados: A média de idades foi de 53,8±16,5 anos, sendo 60% do sexo feminino e 40% masculino. A inflamação foi bilateral em 70 e unilateral em 57 doentes. O tipo de uveíte mais frequente foi a anterior (51,2%), seguida da panuveíte (21,3%), posterior (19,7%), intermédia (3,9%), episclerite (3,2%) e esclerite (0,8%). As etiologias foram agrupadas em: doenças sistémicas (34%), doenças infecciosas (30%), idiopáticas (27%) e patologias oculares específicas (9%). A acuidade visual média nos olhos com uveíte anterior foi 0.8, panuveíte 0.2, uveíte posterior 0.2, uveíte intermédia 0.7, episclerite e esclerite 1.0. Dos 197 olhos com uveíte, 27 (13,7%) foram submetidos a cirurgia de catarata e 5 (2,5%) a cirurgia de glaucoma. Conclusões: Apesar de se tratar de uma amostra relativamente pequena, reveste-se de importância dado ser fundamental conhecer a realidade em cada centro de referência de forma a optimizar os recursos disponíveis e a melhorar a abordagem clínica.

Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate

We retrospectively analyzed a series of 151 cases of cutaneous leishmaniasis treated between 1967 and 1982. One-hundred-and-thirty-nine (92%) patients presented with active lesions and were treated with daily doses of meglumine antimoniate: 81 adults received a 5-ml vial IM and 58 children received 1 to 5ml. Forty-five (32.4%) patients underwent continuous treatment with meglumine antimoniate for 25 to 116 days without rest intervals, and 94 (67.6%) intermittent treatment with 2 to 5 series of meglumine antimoniate. Intermittent series could include schedules of daily IM applications for 10 to 25 days each and intervals varying from 10 to 60 days. Antimony dose was calculated for 66 (47.5%) patients and ranged from 3.9 to 28.7 Sb5+/kg/day. Of these, 35 patients received >10mg and 31 patients <10mg Sb5+/kg/day. Median time of healing was longer for lesions on the legs and feet - 67.5 days versus 48.7 days (p < 0.001) for other sites. However, there were no significant differences in the median time of healing between adults and children, intermittent and continuous regimens or high and low antimony doses. Fifty-one patients were reassessed 5 to 14 years after treatment and showed no evidence of disease. These results support further investigation (clinical trials) on treatment using low doses of antimony.